SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-017745
Filing Date
2023-06-16
Accepted
2023-06-16 17:22:06
Documents
14
Period of Report
2023-06-16
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20230615_8k.htm   iXBRL 8-K 41589
2 EXHIBIT 99.1 ex_534235.htm EX-99.1 11820
  Complete submission text file 0001437749-23-017745.txt   212892

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20230616.xsd EX-101.SCH 4035
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230616_def.xml EX-101.DEF 13890
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230616_lab.xml EX-101.LAB 18202
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230616_pre.xml EX-101.PRE 13912
8 EXTRACTED XBRL INSTANCE DOCUMENT navb20230615_8k_htm.xml XML 4374
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 231022339
SIC: 2835 In Vitro & In Vivo Diagnostic Substances